JP2019506363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506363A5 JP2019506363A5 JP2018526763A JP2018526763A JP2019506363A5 JP 2019506363 A5 JP2019506363 A5 JP 2019506363A5 JP 2018526763 A JP2018526763 A JP 2018526763A JP 2018526763 A JP2018526763 A JP 2018526763A JP 2019506363 A5 JP2019506363 A5 JP 2019506363A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- homology
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 1805
- 125000000539 amino acid group Chemical group 0.000 claims description 879
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 154
- 239000000203 mixture Substances 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 230000002093 peripheral effect Effects 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 12
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 210000004400 mucous membrane Anatomy 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 5
- 206010021263 IgA nephropathy Diseases 0.000 claims description 5
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 4
- 230000004989 O-glycosylation Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 101000830600 Homo sapiens Tumor necrosis factor ligand superfamily member 13 Proteins 0.000 description 27
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 15
- 101000830595 Mus musculus Tumor necrosis factor ligand superfamily member 13 Proteins 0.000 description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 11
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 10
- 239000000178 monomer Substances 0.000 description 9
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 8
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 8
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 6
- 102000056239 human TNFRSF13B Human genes 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 3
- 101100425947 Mus musculus Tnfrsf13b gene Proteins 0.000 description 3
- 101100425747 Mus musculus Tnfrsf17 gene Proteins 0.000 description 3
- 102000046935 human TNFRSF17 Human genes 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
- 208000015865 IgA pemphigus Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100450563 Mus musculus Serpind1 gene Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 description 1
- 206010038546 Renal vasculitis Diseases 0.000 description 1
- 201000005638 acute proliferative glomerulonephritis Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 201000000464 cone-rod dystrophy 2 Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259897P | 2015-11-25 | 2015-11-25 | |
| US62/259,897 | 2015-11-25 | ||
| US201662313684P | 2016-03-25 | 2016-03-25 | |
| US62/313,684 | 2016-03-25 | ||
| US201662399087P | 2016-09-23 | 2016-09-23 | |
| US62/399,087 | 2016-09-23 | ||
| US201662422848P | 2016-11-16 | 2016-11-16 | |
| US62/422,848 | 2016-11-16 | ||
| PCT/US2016/063518 WO2017091683A1 (en) | 2015-11-25 | 2016-11-23 | Antibody molecules to april and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021132222A Division JP7029018B2 (ja) | 2015-11-25 | 2021-08-16 | Ａｐｒｉｌに対する抗体分子およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019506363A JP2019506363A (ja) | 2019-03-07 |
| JP2019506363A5 true JP2019506363A5 (https=) | 2020-01-09 |
Family
ID=57543212
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526763A Ceased JP2019506363A (ja) | 2015-11-25 | 2016-11-23 | Ａｐｒｉｌに対する抗体分子およびその使用 |
| JP2021132222A Active JP7029018B2 (ja) | 2015-11-25 | 2021-08-16 | Ａｐｒｉｌに対する抗体分子およびその使用 |
| JP2022022801A Withdrawn JP2022068288A (ja) | 2015-11-25 | 2022-02-17 | Ａｐｒｉｌに対する抗体分子およびその使用 |
| JP2024043460A Pending JP2024073611A (ja) | 2015-11-25 | 2024-03-19 | Ａｐｒｉｌに対する抗体分子およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021132222A Active JP7029018B2 (ja) | 2015-11-25 | 2021-08-16 | Ａｐｒｉｌに対する抗体分子およびその使用 |
| JP2022022801A Withdrawn JP2022068288A (ja) | 2015-11-25 | 2022-02-17 | Ａｐｒｉｌに対する抗体分子およびその使用 |
| JP2024043460A Pending JP2024073611A (ja) | 2015-11-25 | 2024-03-19 | Ａｐｒｉｌに対する抗体分子およびその使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (9) | US20170145086A1 (https=) |
| EP (2) | EP4285923A3 (https=) |
| JP (4) | JP2019506363A (https=) |
| KR (2) | KR102747820B1 (https=) |
| CN (3) | CN109089419B (https=) |
| AU (2) | AU2016361488B2 (https=) |
| CA (1) | CA3006058A1 (https=) |
| CL (2) | CL2018001372A1 (https=) |
| CO (1) | CO2018006461A2 (https=) |
| DK (1) | DK3380522T5 (https=) |
| ES (1) | ES2970864T3 (https=) |
| FI (1) | FI3380522T3 (https=) |
| HK (1) | HK1254337A1 (https=) |
| HR (1) | HRP20231578T1 (https=) |
| HU (1) | HUE064791T2 (https=) |
| IL (2) | IL259585B2 (https=) |
| LT (1) | LT3380522T (https=) |
| MA (1) | MA43308A (https=) |
| MX (2) | MX2018006385A (https=) |
| MY (1) | MY197345A (https=) |
| PL (1) | PL3380522T3 (https=) |
| PT (1) | PT3380522T (https=) |
| SA (1) | SA518391659B1 (https=) |
| SG (1) | SG11201804309PA (https=) |
| SI (1) | SI3380522T1 (https=) |
| WO (1) | WO2017091683A1 (https=) |
| ZA (1) | ZA201803366B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210340266A1 (en) * | 2008-10-09 | 2021-11-04 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| CA2936865A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| HK1256417A1 (zh) | 2015-09-11 | 2019-09-20 | 达纳-法伯癌症研究所股份有限公司 | 氰基噻吩并三唑并二氮杂环庚三烯及其用途 |
| MX2018006499A (es) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
| DK3380522T5 (da) | 2015-11-25 | 2024-09-30 | Visterra Inc | Antistofmolekyler til april og anvendelser deraf |
| WO2020139834A1 (en) * | 2018-12-24 | 2020-07-02 | Visterra, Inc. | Methods for identifying epitopes and paratopes |
| AU2020225631A1 (en) | 2019-02-22 | 2021-09-16 | Memorial Sloan Kettering Cancer Center | CD33 antibodies and methods of using the same to treat cancer |
| CN110522902B (zh) * | 2019-09-25 | 2022-10-11 | 南京农业大学 | 一种用于建立慢性肾病模型的组合物及其应用 |
| US20230052256A1 (en) * | 2019-12-24 | 2023-02-16 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
| IL296358A (en) * | 2020-03-13 | 2022-11-01 | Janssen Biotech Inc | Materials and methods for modulating delta chain mediated immunity |
| JP7748393B2 (ja) | 2020-05-08 | 2025-10-02 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
| TW202216195A (zh) | 2020-06-24 | 2022-05-01 | 美商威特拉公司 | April抗體分子及其用途 |
| WO2022081716A1 (en) * | 2020-10-13 | 2022-04-21 | Accubit LLC - Biotechnology | Methods of treating iga nephropathy with thiol-containing molecules |
| AR123935A1 (es) | 2020-10-28 | 2023-01-25 | Janssen Biotech Inc | COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g |
| CN112730851B (zh) * | 2021-03-31 | 2021-06-22 | 南京立顶医疗科技有限公司 | 一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒 |
| US20240228626A1 (en) * | 2021-05-04 | 2024-07-11 | Immunorizon Ltd. | Anti-nkg2d antibodies and uses thereof |
| KR20240019124A (ko) | 2021-05-07 | 2024-02-14 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법 |
| KR20240021179A (ko) * | 2021-05-14 | 2024-02-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 폴리펩티드 및 사용 방법 |
| WO2023150778A1 (en) | 2022-02-07 | 2023-08-10 | Visterra, Inc. | Anti-idiotype antibody molecules and uses thereof |
| US20240092921A1 (en) * | 2022-04-25 | 2024-03-21 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
| CN119930816A (zh) * | 2023-11-02 | 2025-05-06 | 广东菲鹏制药股份有限公司 | 抗cd39人源化抗体或其抗原结合片段及其应用 |
| WO2026067804A1 (zh) * | 2024-09-30 | 2026-04-02 | 信立泰(成都)生物技术有限公司 | 一种抗april抗体或其抗原结合片段及用途 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| ATE352612T1 (de) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| SK3542000A3 (en) | 1997-09-12 | 2000-08-14 | Apotech R & D Sa | Nucleic acid coding ligand april, a vector, a host cell, method for preparing ligand april, a polypeptide of ligand april, a pharmaceutical composition and an antibody, and use thereof |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| CA2396793A1 (en) | 2000-02-16 | 2001-08-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| US20020086018A1 (en) | 2000-05-12 | 2002-07-04 | Theill Lars Eyde | Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI |
| JP2004537290A (ja) * | 2001-05-24 | 2004-12-16 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体 |
| CA2554526A1 (en) | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of bcma and uses thereof |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| ATE500275T1 (de) * | 2005-09-26 | 2011-03-15 | Enzo Life Sciences Els Ag | Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten |
| JP5426531B2 (ja) | 2007-03-27 | 2014-02-26 | ザイモジェネティクス， インコーポレイテッド | 自己免疫疾患の治療のためのＢＬｙＳ阻害および／またはＡＰＲＩＬ阻害ならびに免疫抑制剤の組み合わせ |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| JP5314033B2 (ja) * | 2007-10-22 | 2013-10-16 | メルク セローノ ソシエテ アノニム | 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ |
| AU2009241442B2 (en) * | 2008-05-01 | 2014-11-27 | Zymogenetics, Inc. | Levels of BLyS/ APRIL heterotrimers in serum and use in diagnostic methods |
| US20210340266A1 (en) | 2008-10-09 | 2021-11-04 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| CA2919467C (en) * | 2009-03-02 | 2018-04-17 | Jan Paul Medema | Antibodies against a proliferating inducing ligand (april) |
| EP2488200A4 (en) * | 2009-10-14 | 2013-06-12 | Merck Sharp & Dohme | APRIL ANTAGONISTS AND METHOD FOR THEIR USE |
| ES2751549T3 (es) * | 2009-11-30 | 2020-04-01 | Janssen Biotech Inc | Mutantes de anticuerpos Fc con funciones efectoras ablacionadas |
| CN103249742B (zh) * | 2010-09-16 | 2017-04-12 | 巴利奥医药股份公司 | 抗人肿瘤坏死因子1型受体抗体 |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| CA2833820C (en) * | 2011-05-27 | 2019-10-29 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| PL2718322T3 (pl) * | 2011-06-06 | 2019-07-31 | Novo Nordisk A/S | Lecznicze przeciwciała |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| HK1219740A1 (zh) * | 2013-03-15 | 2017-04-13 | Biogen Ma Inc. | 使用抗αVβ5抗体治疗和预防急性肾损伤 |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| ES2884255T3 (es) * | 2013-11-06 | 2021-12-10 | Janssen Biotech Inc | Anticuerpos anti-CCL17 |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| EP3245230B1 (en) | 2015-01-15 | 2020-12-16 | Université Grenoble Alpes | Anti april (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer |
| DK3380522T5 (da) | 2015-11-25 | 2024-09-30 | Visterra Inc | Antistofmolekyler til april og anvendelser deraf |
| CN105390742A (zh) * | 2015-12-31 | 2016-03-09 | 石家庄圣泰化工有限公司 | 高电压锂离子电池电解液及其制备方法及应用 |
| WO2020144535A1 (en) | 2019-01-08 | 2020-07-16 | Aduro Biotech Holdings, Europe B.V. | Methods and compositions for treatment of multiple myeloma |
| TW202216195A (zh) | 2020-06-24 | 2022-05-01 | 美商威特拉公司 | April抗體分子及其用途 |
| WO2023150778A1 (en) | 2022-02-07 | 2023-08-10 | Visterra, Inc. | Anti-idiotype antibody molecules and uses thereof |
| US20240092921A1 (en) | 2022-04-25 | 2024-03-21 | Visterra, Inc. | Antibody molecules to april and uses thereof |
-
2016
- 2016-11-23 DK DK16810195.4T patent/DK3380522T5/da active
- 2016-11-23 EP EP23200975.3A patent/EP4285923A3/en active Pending
- 2016-11-23 ES ES16810195T patent/ES2970864T3/es active Active
- 2016-11-23 KR KR1020187017534A patent/KR102747820B1/ko active Active
- 2016-11-23 WO PCT/US2016/063518 patent/WO2017091683A1/en not_active Ceased
- 2016-11-23 LT LTEPPCT/US2016/063518T patent/LT3380522T/lt unknown
- 2016-11-23 IL IL259585A patent/IL259585B2/en unknown
- 2016-11-23 US US15/360,145 patent/US20170145086A1/en not_active Abandoned
- 2016-11-23 PT PT168101954T patent/PT3380522T/pt unknown
- 2016-11-23 CN CN201680079727.0A patent/CN109089419B/zh active Active
- 2016-11-23 CA CA3006058A patent/CA3006058A1/en active Pending
- 2016-11-23 HU HUE16810195A patent/HUE064791T2/hu unknown
- 2016-11-23 HK HK18113413.2A patent/HK1254337A1/zh unknown
- 2016-11-23 JP JP2018526763A patent/JP2019506363A/ja not_active Ceased
- 2016-11-23 SG SG11201804309PA patent/SG11201804309PA/en unknown
- 2016-11-23 FI FIEP16810195.4T patent/FI3380522T3/fi active
- 2016-11-23 CN CN202410173851.XA patent/CN118027201A/zh active Pending
- 2016-11-23 MY MYPI2018000794A patent/MY197345A/en unknown
- 2016-11-23 IL IL313508A patent/IL313508A/en unknown
- 2016-11-23 CN CN202410173854.3A patent/CN118420760A/zh active Pending
- 2016-11-23 MX MX2018006385A patent/MX2018006385A/es unknown
- 2016-11-23 EP EP16810195.4A patent/EP3380522B1/en active Active
- 2016-11-23 AU AU2016361488A patent/AU2016361488B2/en active Active
- 2016-11-23 HR HRP20231578TT patent/HRP20231578T1/hr unknown
- 2016-11-23 SI SI201631788T patent/SI3380522T1/sl unknown
- 2016-11-23 PL PL16810195.4T patent/PL3380522T3/pl unknown
- 2016-11-23 KR KR1020247042525A patent/KR20250008787A/ko active Pending
- 2016-11-23 MA MA043308A patent/MA43308A/fr unknown
-
2018
- 2018-05-21 ZA ZA2018/03366A patent/ZA201803366B/en unknown
- 2018-05-22 CL CL2018001372A patent/CL2018001372A1/es unknown
- 2018-05-23 SA SA518391659A patent/SA518391659B1/ar unknown
- 2018-05-23 MX MX2024010175A patent/MX2024010175A/es unknown
- 2018-06-22 CO CONC2018/0006461A patent/CO2018006461A2/es unknown
- 2018-12-07 US US16/212,957 patent/US10385123B2/en active Active
-
2019
- 2019-06-28 US US16/456,810 patent/US20190330326A1/en not_active Abandoned
-
2020
- 2020-06-10 US US16/898,024 patent/US10954296B2/en active Active
- 2020-06-25 US US16/912,131 patent/US10968270B2/en active Active
- 2020-06-25 US US16/912,085 patent/US10981982B2/en active Active
- 2020-10-20 US US17/074,857 patent/US11136385B2/en active Active
-
2021
- 2021-08-16 JP JP2021132222A patent/JP7029018B2/ja active Active
- 2021-08-31 US US17/463,319 patent/US12091451B2/en active Active
-
2022
- 2022-02-17 JP JP2022022801A patent/JP2022068288A/ja not_active Withdrawn
-
2023
- 2023-03-20 AU AU2023201698A patent/AU2023201698A1/en active Pending
-
2024
- 2024-01-30 CL CL2024000276A patent/CL2024000276A1/es unknown
- 2024-03-19 JP JP2024043460A patent/JP2024073611A/ja active Pending
- 2024-07-31 US US18/790,750 patent/US20250066464A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506363A5 (https=) | ||
| JP6526189B2 (ja) | 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用 | |
| AU2014248636B2 (en) | Humanized anti-N2 antibodies | |
| WO2018089628A1 (en) | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof | |
| RU2013155029A (ru) | Терапевтические антитела | |
| CA3006058A1 (en) | Antibody molecules to april and uses thereof | |
| WO2017059196A2 (en) | Antagonistic antibodies specifically binding human cd40 and methods of use | |
| US20240059799A1 (en) | Anti-tl1a antibodies and methods of use thereof | |
| JP2022058414A (ja) | 抗ｃｄ１５４抗体及びこれを使用する方法 | |
| CA2871148A1 (en) | Il-6 binding molecules | |
| AU2025275198A1 (en) | BTLA antibodies | |
| WO2022266539A9 (en) | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE | |
| AU2016404449A1 (en) | Trispecific antibodies against IL-17A, IL-17F and another proinflammatory molecule | |
| WO2020128863A1 (en) | Anti-tnf-alpha antibodies | |
| WO2025101982A1 (en) | Anti-migis-alpha antibodies and methods of use thereof | |
| IL325097A (en) | Lymphotoxin receptor agonist binding proteins | |
| RU2021118446A (ru) | Антитело против il-17a и его применение | |
| RU2019131732A (ru) | Антитела человека против семафорина 4d | |
| OA19281A (en) | Trispecific antibodies against II-17A, II-17F and another proinflammatory molecule. | |
| EA040943B1 (ru) | Антитела к cd154 и способы их применения |